Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 27Lymphoid 10Myeloid 8Plasma cell 3Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 3Thyroid Neoplasms 2Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cetuximab 14Cisplatin 12pembrolizumab 11Paclitaxel 9Gemcitabine 9durvalumab 6Nivolumab 6Docetaxel 6toripalimab 5Carboplatin 5Radiotherapy 4Fluorouracil 4Valproic Acid 3Cyclophosphamide 3Capecitabine 3tremelimumab 2spartalizumab 2nimotuzumab 2irinotecan sucrosofate 2fludarabine phosphate 2fludarabine 2cemiplimab 2anlotinib 2Sunitinib 2S 1 (combination) 2Radiation 2Oxaliplatin 2NVP-BKM120 2Methotrexate 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Azacitidine × Head & Neck × Clear all
NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Celgene

Phase 2 Completed
36 enrolled 24 charts
Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡